Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: The TARGET trial

Circulation

Volumn 105, Issue 20, 2002, Pages 2347-2354

  Stone, Gregg W ^a   Moliterno, David J ^a   Bertrand, Michel ^a   Neumann, Franz Josef ^a   Herrmann, Howard C ^a   Powers, Eric R ^a   Grines, Cindy L ^a   Moses, Jeffrey W ^a   Cohen, David J ^a   Cohen, Eric A ^a   Cohen, Marc ^a   Wolski, Kathy ^a   DiBattiste, Peter M ^a   Topol, Eric J ^a  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

Angioplasty; Platelets; Stents

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ACUTE DISEASE; AGED; ANTIBODIES, MONOCLONAL; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ARTERIOSCLEROSIS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STENTS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TYROSINE;

EID: 0037150178     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000017635.82128.8C     Document Type: Article

References (31)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
3. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
4. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
5. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
6. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
7. Novel dosing regimen of eptifibatide in planned coronary stent implantation
8. Glycoprotein IIb/IIIa integrin blockade
9. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
10. Does greater platelet inhibition explain abciximab's superiority in the TARGET trial?
11. Platelet glycoprotein IIb/IIIa antagonists
12. Platelet GP IIb/IIIa blockers
13. Divergent effects of platelet-endothelial cell adhesion molecule-1 and B3 integrin blockade on leukocyte transmigration in vivo
14. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction
15. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial
16. Comparison of platelet activation in unstable and stable angina pectoris and correlation with coronary angiographic findings
17. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes
18. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
19. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: Rationale and design of the TARGET study
20. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
21. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study
22. Inadequate early inhibition with tirofiban in conventional doses: A potential determinant of suboptimal effects after percutaneous coronary intervention
23. Prognostic implication of creatine kinase elevation following elective coronary artery interventions
24. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: A device-specific analysis of 7147 patients
25. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
26. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions
27. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: The EPISTENT Trial
28. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
29. Loading with clopidogrel at the time of coronary artery stenting results in decreased platelet aggregation, GPIIb/IIIa expression and enhanced platelet-leukocyte microparticles formation
30. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: A meta-analysis
31. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial